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558Introduction: Genitourinary conditions in women increase in prevalence with age. Androgens are prerequisite
hormones of estrogen biosynthesis, are produced in larger amounts than estrogens in women, and decrease
throughout adulthood. However, research and treatment for genitourinary complaints have traditionally focused
on estrogens to the exclusion of other potential hormonal influences.
Aim: To summarize and evaluate the evidence that androgens are important for maintaining genitourinary health
in women and that lack of androgenic activity can contribute to the development of symptoms of the genito-
urinary syndrome of menopause.
Methods: The role of androgens in the pathophysiology, diagnosis, and treatment of genitourinary syndrome of
menopause was discussed by an international and multidisciplinary panel during a consensus conference
organized by the International Society for the Study of Women’s Sexual Health. A subgroup further examined
publications from the PubMed database, giving preference to clinical studies or to basic science studies in human
tissues.
Main Outcome Measures: Expert opinion evaluating trophic and functional effects of androgens, their
differences from estrogenic effects, and regulation of androgen and estrogen receptor expression in female
genitourinary tissues.
Results: Androgen receptors have been detected throughout the genitourinary system using immunohisto-
chemical, western blot, ligand binding, and gene expression analyses. Lower circulating testosterone and estradiol
concentrations and various genitourinary conditions have been associated with differential expression of androgen
and estrogen receptors. Supplementation of androgen and/or estrogen in postmenopausal women (local
administration) or in ovariectomized animals (systemic administration) induces tissue-specific responses that
include changes in androgen and estrogen receptor expression, cell growth, mucin production, collagen turnover,
increased perfusion, and neurotransmitter synthesis.
Conclusion: Androgens contribute to the maintenance of genitourinary tissue structure and function. The
effects of androgens can be distinct from those of estrogens or can complement estrogenic action. Androgen-
mediated processes might be involved in the full or partial resolution of genitourinary syndrome of
menopause symptoms in women. Traish AM, Vignozzi L, Simon JA, et al. Role of Androgens in Female
Genitourinary Tissue Structure and Function: Implications in the Genitourinary Syndrome of Menopause.
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Androgens in Female Genitourinary Tissue 559INTRODUCTION
Menopause and aging are associated with decreased biosyn-
thesis of sex steroid hormones resulting in structural and physi-
ologic changes in the genitourinary tract, including, but not
limited to, anatomic alterations in vulvar, clitoral, vestibular,
urethral, vaginal, anterior vaginal wall, periurethral (prostate),
and bladder tissues.1e3 There can be thinning of the epithelium,
decreased vascularity, altered smooth muscle structure, and
decreased collagen and elastin content. Clinically, symptoms and
physical examination findings can include thinning and resorp-
tion of the labia, retraction of the introitus with concomitant
dyspareunia, genital dryness, loss of vaginal rugae, friable vaginal
epithelium with signs of injury (petechiae) and/or inflammation,
increased vaginal pH, protrusion and widening of the urethral
meatus and urethral sensitivity, urinary frequency and urgency,
recurrent urinary tract infections, and decreased lubrication,
vaginal or vestibular discomfort, or pain with or without sexual
activity.4e7 Secondary to these symptoms, there also can be
decreased libido and orgasmic response, significantly affecting
sexual function. In symptomatic women, these changes can cause
significant distress with decreased quality of life8,9 and constitute
part of the diagnosis for genitourinary syndrome of menopause
(GSM).1 GSM is chronic and progressive, increases in severity
over time, and does not improve without treatment.1,10
Sex steroid hormones (androgens, estrogens, and progestins)
play an important role in human reproductive and sexual func-
tion. In particular, androgens and estrogens are critical physio-
logic modulators during development and maintenance of genital
tissue structure and function.1,4e6,11 Despite the longstanding
perspective that pathologic conditions affecting female genital
and urinary tissues are due to estrogen deficiencies,2 the
biochemical and physiologic mechanisms regulating sex steroid
action in the genitourinary system have not been fully investi-
gated and the role of androgens is unrecognized or underap-
preciated. This review examines the evidence that androgens
contribute to genitourinary health in women and that hormonal
insufficiency of androgens and estrogens after menopause can
lead to GSM.METHODS
The International Society for the Study of Women’s Sexual
Health convened a multidisciplinary and international panel of
14 researchers and clinicians in obstetrics and gynecology,
endocrinology, urogynecology, internal medicine, biochemistry,
and physiology. During the 2-day conference, participants
presented and discussed the current state of knowledge on the
pathophysiology, diagnosis, and treatment of GSM and, in
particular, the role of androgens in female genitourinary tissues.
A working subgroup was designated to develop a scientific report
to support a separate clinically focused consensus white paper.
The writing team performed literature reviews using the US
National Center for Biotechnology Information’s PubMedSex Med Rev 2018;6:558e571database on (i) the effects of androgens in female genitourinary
tissues; (ii) distinctions between androgenic and estrogenic
effects; and (iii) regulation of androgen and estrogen receptors
(AR and ER) in premenopausal and postmenopausal women,
intact and ovariectomized animals, and animal models of human
disease. Selection criteria were based on expert opinion and,
whenever possible, preference was given to studies that included
human tissues. There were no filters or restrictions on publica-
tion date. Because treatment recommendations and efficacy of
therapies are not specifically discussed in this review, levels of
evidence have not been included.HORMONAL AND GENITOURINARY CHANGES IN
POSTMENOPAUSAL WOMEN
During early childhood, plasma estradiol concentration
generally remains below 13 pg/mL and gradually increases during
prepuberty and through adolescence.12 Plasma testosterone
concentration in prepubertal girls is lower than 20 ng/dL.12
During the reproductive years, mean plasma estradiol concen-
tration varies throughout the menstrual cycle in women, ranging
from 40 to 350 pg/mL, and mean total testosterone concentra-
tion is 35 ng/dL (range ¼ 20e70 ng/dL).13,14 In healthy
premenopausal women, the vagina has a stratified squamous
epithelium composed of 3 cell layers consisting of superficial and
intermediate cells with few parabasal cells. Normal proliferation
of the epithelium leads to the formation of moist and thick rugae
on the mucosal surface of the vagina and glycogen released by
exfoliated epithelial cells is hydrolyzed into glucose. Then,
glucose is metabolized mainly by lactobacilli into lactic acid,
creating an acidic environment (pH ¼ 3.5e4.5) that discourages
the growth of pathogenic bacteria and fungi.6
During menopause, mean estradiol concentration decreases to
13 pg/mL.14 Although mean testosterone concentration is
decreased slightly to a value of 25 ng/dL,14 it is important to
emphasize that androgen levels progressively decrease throughout
adult life.15,16 Thus, menopause itself is not associated with
dramatic decreases in androgens but postmenopausal women can
have significantly less endogenous androgens compared with
younger women in their 20s and 30s. Interestingly, the
perimenopausal state might be associated with a relatively stable
serum concentration of free testosterone due to decreasing
SHBG, caused in part by decreased estradiol.17 The greatest
decreases in SHBG levels have been reported to occur from 4
years before and up to 2 years after the final menstrual period.17
In the absence of sufficient levels of sex steroid hormones, the
genitourinary organs essentially return to the structure and
function more representative of prepuberty. Vulvar tissue can
appear diminished, obliterated, or even fused, and irritation or
erythema can be evident.18 The introitus becomes narrow with a
loss of hymenal remnants, the cervix can become flush with the
vaginal vault, and pelvic organ prolapse is not uncommon.18 The
vagina can become shortened and narrowed; its surface can
Figure 1. Synthesis of androgens. The major androgen secreted by the adrenals is DHEA, synthesized from cholesterol by the sequential
action of CYP11 and CYP17 enzymes. Testosterone is synthesized from cholesterol in the ovaries and adrenals and from circulating DHEA in
the peripheral tissues. Testosterone and androstenedione are the necessary precursors to the formation of estradiol and estrone. Estrogens
are a minor product of the adrenal glands (dashed rectangle). Androstenedione also can be converted by aromatase to estrone and
interconversion between estradiol and estrone is mediated by multiple isoforms of 17b-HSD. 5a-DHT is synthesized in target tissues from
testosterone by the action of 5a-reductases. Major pathways of synthesis in humans are denoted by blue arrows and minor pathways
are denoted by gray arrows. CYP ¼ cytochrome P450; DHEA ¼ dehydroepiandrosterone; DHT ¼ dihydrotestosterone;
HSD ¼ hydroxysteroid dehydrogenase. Figure 1 is available in color online at www.smr.jsexmed.org.
560 Traish et alappear thinner, less elastic, and smoother (fewer rugae) with
visible petechiae from intradermal or submucosal bleeding or
inflammation. Urethral changes can include development of a
urethral caruncle with urethral prolapse when the mucosa is
circumferentially everted at the meatus. The loss of acidity in the
vagina is associated with decreased resistance to non-native
bacterial or fungal infection and there could be subsequent
development of ascending bladder infections, overactive bladder,
or recurrent urinary tract infections.19ANDROGEN PRODUCTION AND SIGNALING
Androgens are 19-carbon steroid compounds that are synthesized
from cholesterol (Figure 1). The 4 major androgens present in the
systemic circulation of premenopausal women are dehydroepian-
drosterone (DHEA; mostly as DHEA sulfate), androstenedione,
testosterone, and 5a-dihydrotestosterone (5a-DHT). Androstene-
diol is a 5th androgen that is produced in lesser amounts. The
synthesis of androgens in women takes place primarily in the ovaries
and adrenal glands but can be synthesized in peripheral tissues. The
ovaries secrete DHEA 1 to 2 mg/day and androstenedione 1 to 3.5
mg/day (peaking in peri-ovulatory phase) and the adrenal glands
secrete DHEA sulfate 7 to 14 mg/day, DHEA 3 to 4 mg/day, and
androstenedione 1 to 1.5 mg/day.20 Total testosterone productionhas been estimated to be 0.1 to 0.4 mg/day, with the ovaries and
adrenals synthesizing roughly equal amounts.20,21 Similar amounts
of estradiol (0.06e0.4mg/day) are produced by the ovaries.22Thus,
in healthy premenopausal women, production of androgens
(DHEA, androstenedione, and testosterone) is significantly greater
than that of estrogens.
It also is important to note that androgens are the necessary
precursors for the biosynthesis of estrogens (Figure 1).23e25 In the
ovaries, adrenal gland, and peripheral tissues, DHEA and andro-
stenedione can be converted to testosterone, which in turn can be
converted to the more potent androgen 5a-DHT by the action of
5a-reductases or to estradiol by aromatase.26 Aromatase also
converts androstenedione to estrone, a weaker estrogen. A reversible
reaction mediated by multiple isoforms of 17b-hydroxysteroid
dehydrogenase can interconvert estrone and estradiol, but estrogens
(18-carbon steroid compounds) are generally not converted back to
androgens. In postmenopausal women, circulating DHEA and
androstenedione are important precursors for the local synthesis of
testosterone and estradiol in extragonadal tissues.24,26
The classic mechanism of androgen action through the intra-
cellular AR has been well described in previous publications.27,28
Briefly, binding of testosterone or 5a-DHT with the AR in target
cells leads to receptor activation that involves conformational
changes, including dissociation of heat shock proteins, receptorSex Med Rev 2018;6:558e571
Figure 2. AR signaling. ARs are ligand-activated transcriptional regulators. Binding of T or 5a-DHT causes dissociation of HSPs,
conformational change in the AR, and receptor dimerization. Ligand-bound receptor dimers bind to AREs on DNA and organize multiple
transcriptional factors including RNA polymerase, coactivators and/or corepressors (transcriptional complex). Androgen-dependent protein
products exert trophic effects on various genitourinary tissues. AR ¼ androgen receptor; ARE ¼ androgen-response element; DHT ¼
dihydrotestosterone; HSPs ¼ heat shock proteins; T ¼ testosterone. Figure 2 is available in color online at www.smr.jsexmed.org.
Androgens in Female Genitourinary Tissue 561dimerization, and translocalization into the nucleus (Figure 2). This
activated hormone-receptor complex binds to androgen response
elements on the DNA with high affinity. Such specific binding to
androgen response elements recruits transcriptional factors and co-
activators or co-repressors, resulting in increased or decreased
mRNA expression of specific androgen-responsive genes and sub-
sequent changes in protein synthesis and cellularmetabolism.Novel
mechanisms involving non-genomic rapid signaling through cyto-
plasmic and plasma membrane ARs have been reported in neurons
of the central nervous system, prostate cancer cells, and mouse
Sertoli cells.29e35 However, the significance of these signaling
pathways in female genitourinary tissues is not clear and not dis-
cussed in this review.EFFECTS OF ANDROGENS IN FEMALE
GENITOURINARY TISSUES
Although the role of androgens in genitourinary tissues is
based predominantly on data from animal studies, several lines of
evidence from clinical studies and laboratory analyses of human
tissues suggest that androgens also are important in human
genitourinary physiology. Detection of ARs and ERs in genito-
urinary tissues and androgenic effects that are distinct from and
contributory to estrogenic effects are discussed below.Sex Med Rev 2018;6:558e571Vagina
AR protein immunoreactivity and mRNA were detected
throughout the human vagina (mucosa, submucosa, stroma,
smooth muscle, and vascular endothelium).36e38 Similar find-
ings of positive AR immunoreactivity in the epithelium, lamina
propria, blood vessels, and muscularis layer were reported in
monkey vagina.39 In addition, enzymes involved in androgen
biosynthesis (17b-hydroxysteroid dehydrogenase and 5a-reduc-
tase) were expressed at high levels in the stratified squamous
epithelium of monkey vagina and at lower levels in the muscu-
laris layer and in the walls of blood vessels.39
ER is present in the epithelium and in stromal and muscle
cells of the human vagina.40,41 Interestingly, immunostaining for
ER and AR was observed in epithelium, stroma, and smooth
muscle of canine vagina and vulva but ER and AR staining
intensity was generally higher in the stroma than in the epithe-
lium.42 Although direct evidence was not provided in this study,
the investigators hypothesized that stromal-epithelial (paracrine)
interactions might be important in mediating the effects of
androgens and estrogens, particularly to the differentiation of
vaginal epithelium.
It is well established that estrogen stimulates cell proliferation
and thickening of the human vaginal epithelium.43 More recent
studies confirmed that epithelia throughout the lower urinary
562 Traish et altract of women exhibit increased proliferation in response to
estrogen.44 Less recognized is the observation that androgens also
could independently regulate vaginal health.45 Initial observa-
tions that vaginal atrophy was less prevalent in postmenopausal
women with higher levels of androstenedione and testos-
terone46,47 left open the possibility that testosterone could be
converted to estradiol by aromatase. However, in a small study in
women (N ¼ 21) with breast cancer undergoing aromatase in-
hibitor therapy, intravaginal (vaginal mucosa) application of
testosterone for 4 weeks was shown to ameliorate the signs and
symptoms of vaginal atrophy (dyspareunia, vaginal dryness,
vaginal pH, and epithelial maturation),48 suggesting that
androgens could have an independent effect on epithelial growth.
As noted earlier, circulating DHEA can be locally converted in
genitourinary tissues to androgens and estrogens that bind AR
and ER.26 Thus, the effects of DHEA also could provide sup-
portive evidence for androgens and estrogens in maintaining
genitourinary tissue health. Indeed, in a randomized, double-
blinded, placebo-controlled trial evaluating intravaginal DHEA
for treating symptoms of GSM, daily application for 12 weeks in
postmenopausal women improved vaginal pH, superficial and
basal epithelial cell counts and relieved dyspareunia.49 Currently,
it remains unclear to what extent these clinical improvements can
be attributed AR vs ER activation and it is generally assumed that
androgen and estrogen metabolites of DHEA provide benefit.
Limited evidence in cell lines and rodent models of diabetes,
chemical carcinogenesis, and obesity suggests that DHEA also
could act independently through specific membrane receptors or
facilitate the activation of other receptor systems.50e53 Further, a
G-protein-coupled membrane receptor in bovine aortic endo-
thelial cells that activates endothelial nitric oxide synthase has
been reported.54 Although a specific DHEA receptor has not
been demonstrated in human tissues or cells, future research
could uncover additional mechanisms of action of DHEA that go
beyond the traditional view of this steroid as a prohormone.55
Vaginal perfusion also is regulated by androgens and estrogens
in the context of baseline blood flow and during sexual arousal.
Esterified estrogens increased baseline genital blood flow in
postmenopausal women,56 whereas testosterone or estradiol
administration in ovariectomized rats restored vaginal blood flow
responses to pelvic nerve stimulation.57e59 Although specific
mechanisms have yet to be characterized, testosterone and
estradiol differentially regulate the expression of nitric oxide
synthase and arginase,60 key proteins regulating vaginal blood
flow.61,62 Interestingly, in a small double-blinded, randomized,
placebo-controlled trial of 8 healthy women, vaginal vaso-
congestion and genital sensation in response to visual sexual
stimulation was significantly increased 3 to 4.5 hours after sub-
lingual administration of a single dose (0.5 mg) of testosterone
undecanoate.63 Although testosterone has been shown to have
acute vasodilatory effects in other vascular beds,64,65 the
enhancement in vaginal response to visual sexual stimulation was
significantly delayed in relation to peak plasma levels of testos-terone that occurred 15 minutes after dosing and returned to
baseline levels within 90 minutes. Conceivably, measurable in-
creases in vaginal vasocongestion could require testosterone-
induced upregulation of protein synthesis directly within the
vagina and alterations in neuronal signaling pathways in the
brain that process visual sexual stimuli.
In other functional studies in animals, androgens and estro-
gens were shown to regulate vaginal mucin production in
epithelial cells66e71 and to increase norepinephrine content or
increase the density of adrenergic nerves in the vagina.11,72e76 In
more recent studies comparing androgenic and estrogenic effects,
increased vaginal innervation was attributed to androgens but not
to estrogens.75,77 Direct comparisons between studies remain
difficult because of different experimental paradigms (ovariec-
tomy vs pregnancy vs specific hormone administration at
different doses) and different methodologies of estimating
neurotransmitter content or nerve fiber area or density in relation
to tissue atrophy or growth. Nevertheless, although vaginal
epithelial proliferation appears to be primarily an estrogenic ef-
fect, androgens do appear to have a role in regulating vaginal
epithelial function (eg, mucin production). Whether mainte-
nance of innervation requires a combination of androgens and
estrogens or is exclusively an androgenic effect remains unclear.
Interestingly, testosterone replacement in ovariectomized rabbits
caused thickening of the submucosal lamina propria and mus-
cularis layers and enhanced neurogenic and vasoactive intestinal
peptide-induced relaxation of vaginal tissue strips, whereas
estradiol replacement primarily stimulated epithelial thickening
and did not improve neurogenic or vasoactive intestinal peptide-
induced relaxation of the vaginal wall.58 These observations
support the perspective that vaginal health consists of more than
epithelial health and the impact of androgens and estrogens
should be evaluated in a more holistic manner with regard to
overall structure and function.
Bladder, Urethra, Prostate
AR and ER have been detected in the epithelium and smooth
muscle of the urethra and bladder in female rabbits78 and specific
receptor binding sites for estradiol and 5a-DHT were reported in
the urinary tract of female baboons.79 In ovariectomized female
rats, the bladder exhibited changes in tissue histomorphology,
growth factor expression, and contractile responses that were
partly restored by estradiol or testosterone treatment.80e82
Treatment with the combination of estradiol and testosterone
was the most effective. In a separate study, ovariectomized rats
treated with testosterone plus the aromatase inhibitor letrozole to
inhibit the conversion of testosterone to estradiol normalized
bladder relaxation responses to nitroprusside and increased the
degree to which a phosphodiesterase type 5 inhibitor could
potentiate nitroprusside-induced relaxation.83 In female rabbits,
ovariectomy produced urothelial hypoxia because of decreased
blood flow84 and estradiol was shown to improve bladder and
urethral structure and function by increasing tissue vascularity.85Sex Med Rev 2018;6:558e571
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to sex steroid hormones in women is supported by several
correlational studies. Although stress urinary incontinence and
polycystic ovaries are not included within the spectrum of GSM,
the following clinical studies are illustrative of trophic or func-
tional effects of androgens and estrogens in the bladder, prostate,
and urethra of women. Vascular resistance (inversely correlated
with blood flow) was greater in the bladder neck of menopausal
women than premenopausal women and systemic estrogen-
progesterone hormone replacement therapy increased blood
flow in menopausal women with urinary stress incontinence.87
In addition, ultrasound assessment in normal-weight premeno-
pausal women with and without polycystic ovary syndrome
suggested a positive correlation between circulating testosterone
levels and the volume of urethrovaginal tissue.88 Although the
full clinical significance remains unclear, in genitourinary tissue
(vaginal punch biopsies near external urethral meatus) of women
with and without stress urinary incontinence (36e88 years old),
estradiol levels were positively correlated and testosterone levels
were negatively correlated with markers of collagen turnover.89
Insufficient amounts of collagen can lead to laxity or prolapse,
whereas excess collagen accumulation can lead to tissue fibrosis.
Thus, it stands to reason that significant decreases in estrogens
and/or androgens or alterations in ER and/or AR expression can
adversely affect the balance of collagen synthesis and degradation.Clitoris, Labia, Vestibule
Positive immunostaining for AR and ER was demonstrated in
epidermis and dermis of human labial tissue.36,41 Compared
with human vaginal epithelium, there was greater immuno-
staining for AR and less immunostaining for ER in labial skin.36
Similarly, positive immunostaining for AR and ER has been
reported in canine vulvar skin.42 AR has been localized to the
mucin-secreting vestibular (Bartholin) glands in humans90 and
ER has been detected in the vestibular glands of the cat.91
However, aside from the well-known atrophic changes of the
labia and vestibule in postmenopausal women, few studies have
examined the potential clinical relevance of sex steroid hormones
in these tissues.
In a small study examining skin from women with vulval
lichen sclerosus (VLS; n ¼ 7), the epidermal layer was signifi-
cantly thinner but ER and AR immunostaining was similar to
that of women without VLS (n ¼ 8).41 The main difference
occurred in the subdermal fibromuscular layer, where ERa was
the predominant receptor isoform in vulvar smooth muscle of
healthy women but ERb became predominant with concomitant
disappearance of ERa in vulvar smooth muscle of women with
VLS.41 AR was only present in the subdermal vascular layer of
healthy women and absent in the fibromuscular layer of the vulva
of the 2 groups. Because the fibromuscular layers in women with
VLS were negative for Ki-67, a cellular marker for proliferation,
the investigators postulated that the appearance of ERb could
lead to other functional alterations not associated with cellSex Med Rev 2018;6:558e571growth (possibly collagen production), whereas ERa in healthy
women without VLS could stimulate cell growth.41
In a separate study, AR was detected in the vulvar skin of 5 of
39 postmenopausal women with VLS and 4 of the women with
positive staining for AR were asymptomatic.92 However, the
pathophysiology of lichen sclerosis remains unknown93 and
claims of normal function in this patient population should be
interpreted cautiously. Thus, it remains unclear whether AR
expression in vulvar skin confers any benefit with regard to
symptoms experienced by women with VLS, especially because
topical testosterone or 5a-DHT has been deemed ineffective in
treating VLS symptoms.94 With regard to the vestibule,
administration of combined estradiol and testosterone implants
in veal calves was associated with metaplasia and hyperplasia of
the vestibular glands and this response was proposed as a marker
for detecting supplemental administration of naturally occurring
anabolic steroids.95 Although the investigators assumed that this
effect on the vestibular glands was an estrogenic effect, it remains
unclear whether testosterone contributed to the transformational
or proliferative effects.
The clitoris is well established as an androgen responsive organ
during embryonic development but it also maintains androgen
dependency in adulthood because it continues to express sig-
nificant amounts of AR, although most tissues in the developing
female genital tract cease to express AR after the 1st trimester of
pregnancy.96e98 Clitoral hypertrophy or clitoromegaly is
considered one of the most sensitive markers for increased
androgen production in women.99 Yet, even in this androgen-
sensitive organ, estrogen is functionally important. In healthy
eumenorrheic premenopausal women, basal clitoral volume and
blood flow varied during the menstrual cycle. In the absence of
sexual arousal, estradiol levels were positively correlated with
clitoral volume and negatively correlated with vascular resis-
tance.100 In ovariectomized female rats, treatment with testos-
terone was associated with increased endothelium-dependent
vasodilation of the clitoral corpora cavernosa, a critical event for
clitoral tumescence during sexual arousal.101 This effect of
testosterone was not due to conversion to estradiol because
co-administration of testosterone and letrozole, an aromatase
inhibitor, did not abolish the response. Ovariectomy also
impaired clitoral vascular smooth muscle contractile signaling
pathways involving RhoA and RhoA-associated protein kinase
and this was reversed with estradiol treatment.101 Thus, estradiol
and testosterone are necessary for maintenance of clitoral tissue
morphology and signaling pathways that regulate vascular
responsiveness of the clitoris during sexual arousal.Supporting Structures and Pelvic Floor
Similar to other skeletal muscle, ARs are highly prevalent
throughout the pelvic floor musculature.102 AR immunostaining
was strongly detected in biopsies of levator ani muscle from
premenopausal and postmenopausal women.103 In a female rat
model of stress urinary incontinence, a single dose of testosterone
564 Traish et alincreased myofiber area and prevented or ameliorated inconti-
nent symptoms after early or delayed administration of testos-
terone.104 In ovariectomized mice with atrophied pelvic muscles,
treatment with selective AR modulators restored pelvic muscle
mass and genes associated with muscle catabolism were
inhibited.105
Whether ER participates in the regulation of pelvic muscle
growth or function remains unclear because reports are inconsistent.
ER was not detected in the levator ani muscle of women in some
studies,103,106 whereas others did report the presence of ER in the
levator ani muscle of premenopausal and postmenopausal
women.107e109 Nevertheless, as discussed previously with periure-
thral tissue, ER does appear to have a role in regulating connective
tissue and extracellularmatrix. ER, alongwithAR, has beendetected
in the levator ani fascia of women undergoing surgery for gyneco-
logic and urogynecologic conditions.103 ER was increased in the
levator ani fascia of symptomatic women compared with age-
matched and asymptomatic women. In contrast, premenopausal
women with pelvic organ prolapse had significantly lower ER levels
in the cardinal ligament and uterosacral ligament.110 ER also was
decreased in periurethral fascia samples from menopausal women
with stress urinary incontinence.111 Whether these differences are
due to the various tissues, anatomic locations, and/or conditions
remains to be elucidated.Somato-sensation
In general, women are more likely to experience chronic pain
syndromes compared with men and this sex disparity has pro-
vided a rationale for investigating the role of sex steroid hor-
mones in sensory perception and nociception. Symptoms and
perception of pain are known to vary throughout the menstrual
cycle in women diagnosed with chronic pelvic pain, painful
bladder syndrome, and irritable bowel syndrome.112 However,
the effects of androgens and estrogens on attenuating or poten-
tiating nociception are complex and not consistently predictable.
Lower estradiol concentration was associated with weaker
emotional control (reflective of central neuromodulation) over
peripheral pain stimuli in healthy, normally cycling premeno-
pausal women.113 In a separate study of healthy premenopausal
women assessing interindividual differences in pain perception
using the McGill Pain Questionnaire, serum testosterone was
positively correlated with an antinociceptive effect and serum
estradiol was correlated with a pro-nociceptive effect.114 In
women with fibromyalgia not receiving hormone therapy (age
range ¼ 42e55 years), daily topical treatment with 1% testos-
terone gel 0.75 g improved self-reported symptoms related to this
chronic pain condition (muscle pain, stiffness, and fatigue).115
Although various experimental paradigms have attempted to
discern the differences between central and peripheral effects,
these types of clinical studies highlight the fact that the effects of
androgens and estrogens on central mechanisms of pain
perception are intimately associated with any potential peripheral
effects on sensory nerves.Immunohistochemical studies of vaginal tissue biopsies from
postmenopausal women have demonstrated that total nerve
density was highest in patients not receiving hormone therapy,
moderate in those receiving systemic estrogen therapy, and
lowest in those receiving intravaginal estrogen therapy.116 This
downregulation included parasympathetic, sympathetic, and
sensory nerves. These findings also are supported by studies in
female rats. Compared with rats in estrus, total nerve density was
increased by 59% in vaginal tissue of ovariectomized rats and
these effects persisted after correcting for differences in vaginal
tissue volume.117 When ovariectomized rats were treated with
estradiol, the nerve density was decreased to levels that were
similar to intact rats in estrus.117 The investigators postulated
that decreasing estrogen levels during menopause could increase
sympathetic and sensory nerve density, leading to vasoconstric-
tion, vaginal dryness, and pain.117
In functional studies, estrogen has been shown to increase the
size of the sensory field for the pudendal nerve in female rats.118
ERa protein and mRNA for ERa and ERb have been detected
in neurons of lumbosacral dorsal root ganglia119 and could be
important for growth and maintenance of sensory nerve path-
ways.120 Estrogen also has been shown to enhance the response
to opioids in rats and non-human primates,121,122 although this
is not a consistent finding.123 Thus, data suggest that androgens
and estrogens can modulate sensory nerve function and/or sen-
sory perception. However, specific findings in genitourinary
tissues are extremely limited and future research in this area
would prove valuable to characterizing mechanisms of hyper-
sensitivity and pain in GSM.REGULATION OF AR AND ER EXPRESSION IN
FEMALE GENITOURINARY TISSUES
Receptor protein expression is a critical mechanism regulating
tissue responsiveness to hormones. Self-regulation and cross-
regulation of AR and ER by androgens and estrogens can
modulate the effects of sex steroid hormones in genitourinary
tissues.Regulation of AR by Testosterone
In vaginal tissue from women undergoing surgery for pelvic
organ prolapse, AR protein and mRNA expression were signifi-
cantly decreased in postmenopausal women compared with
premenopausal women.38 In a separate study examining tissue
from women undergoing surgery for incontinence or pelvic or-
gan prolapse, older age was correlated with decreased AR im-
munostaining in the vaginal epithelium.37 Although plasma
testosterone concentration was not available for all groups in
these studies, the downregulation of AR expression is presumably
further correlated with the well-documented decrease in andro-
gens with advancing age.
In women treated with long-term administration of high-dose
testosterone (Testoviron depot 100 mg intramuscularly everySex Med Rev 2018;6:558e571
Androgens in Female Genitourinary Tissue 5657e10 days for 1 year) before female-to-male gender reassign-
ment surgery, AR mRNA expression was significantly greater in
vaginal tissue compared with that in postmenopausal women.38
Similarly, ovariectomy of rats resulted in downregulation of AR
expression, and testosterone replacement restored AR expression
in the vagina, as assessed by ligand binding assays and western
blot analyses.59 Immunostaining studies also demonstrated
increased AR density in the vaginal muscularis of ovariectomized
rats supplemented with testosterone.124 Thus, circulating
testosterone is positively correlated with AR expression in the
vagina. Whether a critical concentration of testosterone is
required to maintain adequate levels of AR remains unknown.Regulation of ER by Estrogen
In women undergoing surgery for urogynecologic conditions,
ERa mRNA increased in the vagina of postmenopausal women
and decreased after systemic estrogen-progestin replacement
therapy, but not with intravaginal estrogen.125 Although the exact
types of hormone therapy were not specified, lower doses of
estrogen were presumably used for intravaginal application
compared with systemic administration. These findings are
consistent with animal studies. Functional ER, assessed by
immunostaining and binding of [3H]estradiol, increased in vaginal
tissue extracts of ovariectomized rats and decreased in ovariecto-
mized rats supplemented with estradiol to physiologic levels.57,124
However, ER remained elevated in vaginal tissue extracts of
ovariectomized rats supplemented with sub-physiologic levels of
estradiol.57,110 In the same study, similar findings were obtained
when ER was assessed by western blots.57 In canine vagina,
significant negative correlations were found between serum
estradiol concentration and ERa immunostaining in epithelial and
stromal cells, suggesting a negative feedback mechanism between
estradiol and its receptor.42 However, other investigators have not
observed such reciprocal regulation between estradiol and ER. In a
small cohort of patients undergoing surgery for vaginal prolapse,
ERa immunostaining was significantly decreased in the vaginal
mucosa but not in the vaginal stroma of postmenopausal women
compared with premenopausal women.126 ERb was decreased in
the stroma but not in the mucosa of postmenopausal women.126
Although the significance of this differential regulation of ER
subtypes remains unclear, this last study found an overall decrease
in total ER in the vagina in postmenopausal women. It is unlikely
that this inconsistency is due to differences in species or assessment
technique because previous studies reported consistent findings
among human, rat, and dog vaginal tissue using immunostaining,
western blotting, and receptor binding assays.42,57,124,125 Future
studies should investigate potential differences between specific
urogynecologic conditions and vaginal tissue (proximal vs distal vs
periurethral).Cross-Regulation of AR and ER
In addition to testosterone, 5a-DHT, and estradiol regulating
their receptors, each hormone could cross-regulate the otherSex Med Rev 2018;6:558e571receptor. In postmenopausal women receiving oral or transdermal
estrogen replacement therapy, AR expression in the vaginal sub-
mucosa was significantly decreased compared with untreated
postmenopausal women.37 In ovariectomized rats, estradiol
administration at physiologic levels decreased AR immunostaining
in the vaginal epithelium and muscularis.124 Although these
changes in the rat vagina did not reach statistical significance (likely
because of the large number of treatment groups compared), on
average, AR immunostaining decreased 43% in the epithelium
and 27% in the muscularis.124 These findings suggest that estro-
gen could downregulate AR expression in the vagina.
As mentioned earlier, immunostaining for hormone receptors
was performed in vaginal tissue from women undergoing long-
term treatment of high-dose testosterone before gender reas-
signment surgery.38,126 Testosterone treatment decreased the
expression of ERa and ERb in the stromal and epithelial layers
compared with premenopausal women.126 Further, testosterone
administration induced profound morphologic changes to the
vagina, manifested primarily as thinning of the vaginal epithe-
lium and loss of glycogen content.126 Unlike the effect of
testosterone on AR expression, the effects of testosterone on ER
have not been confirmed in animal studies. For example, in
ovariectomized rats administered physiologic levels of testos-
terone, ER expression remained elevated at levels that were
similar to ovariectomized rats treated with vehicle.124 Thus, it
remains unclear whether cross-regulation of ER by testosterone
occurs in the vagina. Currently, the findings of ER down-
regulation by testosterone in women undergoing gender
reassignment surgery should be interpreted cautiously until
further studies can corroborate these data.Receptor Polymorphisms
Aside from changes in expression of AR and ER proteins,
hormone receptor polymorphisms could influence susceptibility
to certain clinically significant conditions as hormone levels
decrease. For example, in a small study of women taking
combined hormonal contraceptives, those who developed vesti-
bulodynia were more likely to have longer CAG repeats in the
AR gene, a genetic characteristic associated with decreased
responsiveness to androgens in target tissues.127e130 Therefore, it
can be speculated that the risk of developing vestibulodynia is
due to lowered androgenic activity in the vulva. Another example
is that the ERa genetic polymorphism rs2228480 G/A was
significantly associated with pelvic organ prolapse in 2 separate
studies.131,132 Thus, genetic polymorphisms of receptors add
another layer of complexity in understanding the molecular
etiology of pathologic conditions.SUMMARY AND CONCLUSIONS
Taken together, clinical and laboratory studies in human and
animal tissues strongly suggest that decreasing androgens with
advancing age and cessation of estrogen production during
566 Traish et almenopause are important contributory factors in the develop-
ment of the signs and symptoms of GSM. The actions of
androgens can be distinct from those of estrogens and the ef-
fects of testosterone do not necessarily require its conversion to
estradiol by aromatase. The most readily available clinical ob-
servations of androgenic trophic effects on the clitoris and es-
trogenic trophic effects on the labia and vaginal mucosa have
likely resulted in an oversimplified understanding of the role of
sex steroid hormones in genitourinary physiology and patho-
physiology. The distinct regulation of AR and ER in different
tissue layers of the vagina and the specific responses to
androgen or estrogen administration is a prime example illus-
trating the perspective that a given sex steroid hormone cannot
fully maintain tissue structure and function by itself. In addi-
tion, clinical assessments of genitourinary health (eg, parameters
of epithelial health in the vagina, pain sensitivity, pallor, ery-
thema, and dryness) are limited and do not necessarily reflect
the health of the entire organ, especially when genitourinary
system function is challenged by sexual activity.
Understanding the role of sex steroid hormones in genital and
urinary tissues must go beyond the simple correlations with
plasma levels of a given hormone. Downregulation or upregu-
lation of receptors in target tissues could limit or enhance the
action of a given concentration of androgens and estrogens in the
circulation. Receptor subtypes with different signaling pathways
and receptor polymorphisms that can alter interactions with
other macromolecules add to the complexity of responses.
Moreover, local synthesis of androgens and estrogens within
genitourinary tissues can have physiologic effects that are not
accurately reflected in assays of blood samples. A more complete
understanding of the molecular mechanisms and individual ac-
tions associated with ARs and ERs could facilitate discovery of
tissue-selective drugs that maximize beneficial effects and limit
adverse effects of hormone therapy.ACKNOWLEDGMENTS
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